Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response

The potency of Toll-like receptor 9 (TLR9) agonist to drive innate immune response was limited due to immune suppression or tolerance during TLR9 signaling activation in immune cells. Herein we addressed this problem by introducing hydroxyapatite nanoparticles (HANPs) to CpG ODN (CpG), a TLR9 agonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qin, Wang, Ruiqi, Hua, Yuchen, Wu, Hongfeng, Chen, Xuening, Xiao, You-cai, Ao, Qiang, Zhu, Xiangdong, Zhang, Xingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tsinghua University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308403/
https://www.ncbi.nlm.nih.gov/pubmed/35911480
http://dx.doi.org/10.1007/s12274-022-4683-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308403/
https://www.ncbi.nlm.nih.gov/pubmed/35911480
http://dx.doi.org/10.1007/s12274-022-4683-x

Ejemplares similares